Is It Possible to Compare PSA Recurrence-Free Survival After Surgery and Radiotherapy Using Revised ASTRO Criterion-"Nadir + 2"?

Urology

Volumn 72, Issue 2, 2008, Pages 389-393

  Nielsen, Matthew E ^a   Makarov, Danil V ^a   Humphreys, Elizabeth ^a   Mangold, Leslie ^a   Partin, Alan W ^a   Walsh, Patrick C ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ARTICLE; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER SURGERY; CANCER SURVIVAL; CONTROLLED STUDY; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROGNOSIS; PROSTATE CANCER; PROSTATECTOMY; TREATMENT FAILURE;

AGED; DIGITAL RECTAL EXAMINATION; DISEASE-FREE SURVIVAL; HUMANS; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; PROSTATE-SPECIFIC ANTIGEN; PROSTATECTOMY; PROSTATIC NEOPLASMS; RETROSPECTIVE STUDIES;

EID: 48349105919     PISSN: 00904295     EISSN: 15279995     Source Type: Journal    
DOI: 10.1016/j.urology.2007.10.053     Document Type: Article

References (23)

1. Kuriyama M., Wang M.C., Lee C.I., et al. Use of human prostate-specific antigen in monitoring prostate cancer. Cancer Res 41 (1981) 3874-3876
2. Lange P.H., Ercole C.J., Lightner D.J., et al. The value of serum prostate specific antigen determinations before and after radical prostatectomy. J Urol 141 (1989) 873-879
3. Oesterling J.E., Chan D.W., Epstein J.I., et al. Prostate specific antigen in the preoperative and postoperative evaluation of localized prostatic cancer treated with radical prostatectomy. J Urol 139 (1988) 766-772
4. Ragde H., Elgamal A.A., Snow P.B., et al. Ten-year disease free survival after transperineal sonography-guided iodine-125 brachytherapy with or without 45-Gray external beam irradiation in the treatment of patients with clinically localized, low to high Gleason grade prostate carcinoma. Cancer 83 (1998) 989-1001
5. D'Amico A.V., Whittington R., Malkowicz S.B., et al. Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer. JAMA 280 (1998) 969-974
6. D'Amico A.V., Whittington R., Malkowicz S.B., et al. Biochemical outcome after radical prostatectomy or external beam radiation therapy for patients with clinically localized prostate carcinoma in the prostate specific antigen era. Cancer 95 (2002) 281-286
7. Trapasso J.G., deKernion J.B., Smith R.B., et al. The incidence and significance of detectable levels of serum prostate specific antigen after radical prostatectomy. J Urol 152 (1994) 1821-1825
8. Freedland S.J., Sutter M.E., Dorey F., et al. Defining the ideal cutpoint for determining PSA recurrence after radical prostatectomy. Urology 61 (2003) 365-369
9. Cookson M.S., Aus G., Burnett A.L., et al. Variation in the definition of biochemical recurrence in patients treated for localized prostate cancer: the American Urological Association Prostate Guidelines for Localized Prostate Cancer Update Panel report and recommendations for a standard in the reporting of surgical outcomes. J Urol 177 (2007) 540-545
10. Lee W.R., Hanlon A.L., and Hanks G.E. Prostate specific antigen nadir following external beam radiation therapy for clinically localized prostate cancer: the relationship between nadir level and disease-free survival. J Urol 156 (1996) 450-453
11. Critz F.A., Levinson A.K., Williams W.H., et al. The PSA nadir that indicates potential cure after radiotherapy for prostate cancer. Urology 49 (1997) 322-326
12. American Society for Therapeutic Radiology and Oncology Consensus Panel. Consensus statement: guidelines for PSA following radiation therapy. Int J Radiat Oncol Biol Phys 37 (1997) 1035-1041
13. Gretzer M.B., Trock B.J., Han M., et al. A critical analysis of the interpretation of biochemical failure in surgically treated patients using the American Society for Therapeutic Radiation and Oncology criteria. J Urol 168 (2002) 1419-1422
14. Amling C.L., Bergstralh E.J., Blute M.L., et al. Defining prostate specific antigen progression after radical prostatectomy: what is the most appropriate cut point?. J Urol 165 (2001) 1146-1151
15. Critz F.A. A standard definition of disease freedom is needed for prostate cancer: undetectable prostate specific antigen compared with the American Society of Therapeutic Radiology and Oncology consensus definition. J Urol 167 (2002) 1310-1313
16. Kuban D., Thames H., Levy L., et al. Failure definition-dependent differences in outcome following radiation for localized prostate cancer: can one size fit all?. Int J Radiat Oncol Biol Phys 61 (2005) 409-414
17. Horwitz E.M., Thames H.D., Kuban D.A., et al. Definitions of biochemical failure that best predict clinical failure in patients with prostate cancer treated with external beam radiation alone: a multi-institutional pooled analysis. J Urol 173 (2005) 797-802
18. Roach III M., Hanks G., Thames Jr. H., et al. Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: recommendations of the RTOG-ASTRO Phoenix Consensus Conference. Int J Radiat Oncol Biol Phys 65 (2006) 965-974
19. D'Amico A.V., Whittington R., Malkowicz S.B., et al. Predicting prostate specific antigen outcome preoperatively in the prostate specific antigen era. J Urol 166 (2001) 2185-2188
20. Stephenson A.J., Kattan M.W., Eastham J.A., et al. Defining biochemical recurrence of prostate cancer after radical prostatectomy: a proposal for a standardized definition. J Clin Oncol 24 (2006) 3973-3978
21. Leventis A.K., Shariat S.F., Kattan M.W., et al. Prediction of response to salvage radiation therapy in patients with prostate cancer recurrence after radical prostatectomy. J Clin Oncol 19 (2001) 1030-1039
22. Rogers C.G., Khan M.A., Miller C.M., et al. Natural history of disease progression in patients who fail to achieve an undetectable prostate-specific antigen level after undergoing radical prostatectomy. Cancer 101 (2004) 2549-2556
23. Thompson I., Thrasher J.B., Aus G., et al. Guideline for the management of clinically localized prostate cancer: 2007 update. J Urol 177 (2007) 2106-2131